Luminex platform: quantitative protein and RNA assays with superior throughput

The Luminex platform comprises Luminex instruments and multiplex assays for measuring RNA and protein targets. Luminex multiplex assays use xMAP bead-based technology to simultaneously detect and quantitate multiple secreted proteins including cytokines, chemokines, and growth factors. This multiplex technology can also be used to measure gene expression utilizing the Invitrogen QuantiGene Plex assays. The Luminex system produces results comparable to conventional assays such as ELISA and qPCR but with greater efficiency and throughput.


Gain valuable insights about gene expression and protein pathways by measuring more data points from a single sample. Employ the power of multiplexing protein- and gene-level measurements on a single Luminex platform (see related publication). Preconfigured or custom 96- to high-throughput 384-well assays address your most valuable targets.


Complete Luminex portfolio available

As a Luminex partner, we directly offer the entire Luminex portfolio of multiplexing instruments.

Multiplex protein assays

Combine up to 80 protein targets from complex biological samples, with flexible options from preconfigured solutions to custom mixed panels.

Gene expression directly from a lysate

Multiplex up to 80 RNA gene expression targets. Custom and preconfigured panels are available based on your genes of interest.

How does it work

Luminex xMAP (Multi-Analyte Profiling) technology with labeled beads enables scientists to measure multiple proteins or RNA targets in a single well.

Select from over 600 proteins

Invitrogen ProcartaPlex immunoassays cover more than 600 cytokines, chemokines, growth factors, and other protein targets from human, mouse, rat, non-human primate, canine, and porcine.

Get up to 30,720 data points in one plate

Both QuantiGene Plex and ProcartaPlex assays are available in 384-well formats for higher-throughput applications.

For Research Use Only. Not for use in diagnostic procedures.